Novo Nordisk just got a big win from the FDA, and it could change the weight-loss medicine industry again. A new launch could reshape obesity

Jonathan Van Ness is showing off his figure after openly discussing his GLP-1 weight loss. “Sorry not sorry for leading with abs before Antoni &

Quick Read Eli Lilly (LLY) achieved 54% year-over-year revenue growth to $17.6B in Q3. Tirzepatide is projected as the top-selling drug by 2030. Lilly raised

Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production

“Improving access to GLP-1 treatments in the coming years will be a key driver for the Indian pharmaceutical industry, helping address the growing burden of

Comments

21st CENTURY PROBLEMS: I started a GLP-1 to save my own life. How friends reacted surprised me. I got on Ozempic after my doctor predicted

Background: Glucagon-like peptide-1 receptor (GLP-1R) agonists have recently been suggested as effective therapies to treat or reduce the risk of developing secondary lymphedema in patients

A daily Wegovy pill has been approved for use in the U.S. When can you get it?  San Antonio Express-News Weight-loss pill approval set to accelerate

Should You Invest in Ozempic Maker Novo Nordisk in 2026?  The Motley Fool Weight-loss pill approval set to accelerate food industry product overhauls  Reuters Best Semaglutide Options

Women, seeking muscle gains and weight loss, are driving innovation in the protein snack segment. Mohammed Saad/Anadolu via Getty Images Women, seeking muscle gains and

JCM, Vol. 15, Pages 222: Clinical Outcomes Associated with the Use of a Family-Based Digital Support Program in Patients with Pharmacologic Treatment for Obesity Journal

Alright, hear me out before you downvote me into oblivion. I’ve been thinking a lot about the sudden, aggressive push behind these GLP-1 drugs like

submitted by /u/ddx-me [link] [comments]

$ISRG – Deciphering the Durability of a Surgical Revolution Intuitive Surgical, Inc. BATS:ISRG KalaGhazi Intuitive Surgical, Inc. (NASDAQ: ISRG) stands at a critical inflection point

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1)

Quick Read The iShares Biotechnology ETF is up 30% year to date versus 17% for the S&P 500. IBM trades at 36.1x trailing P/E with

Is there a more popular health trend right now than GLP-1 agonist obesity drugs such as Ozempic? Probably not. Ironically, though, investing in Ozempic, or

Research from this year shows vitamin D, meditation, GLP-1 drugs and social connections could slow aging

(MedPage Today) — GLP-1 agonists may have little impact on risk of obesity-related cancers, according to a systematic review and meta-analysis of randomized studies. (Annals

In 2025, fitness and eating habits shifted towards long-term health. Japanese walking, Hyrox-style races, and power training became widely popular. AI trainers and fitness festivals

New research from Cornell University reveals that GLP-1 weight-loss medications are significantly altering American shopping habits. Within six months of starting these drugs, individuals reduced

Intuitive Surgical’s ISRG third-quarter results reignited the long-running debate around the durability of its growth engine. Combined da Vinci and Ion procedures rose 20% year

Alert to readers: Amazon.com displays listings for several more workbooks, study guides, and cookbooks purportedly based on my book, What to Eat Now (see previous post

Packaged food makers and fast-food restaurants may be forced to overhaul more of their products next year as newly approved, appetite-suppressing GLP-1 pills become… Reuters

Healthcare, Vol. 14, Pages 60: 12-Month Weight Loss and Adherence Predictors in a Real-World UK Tirzepatide-Supported Digital Obesity Service: A Retrospective Cohort Analysis Healthcare doi:

This week, The Daily is revisiting some of our favorite episodes of the year and checking in on what has happened in the time since.

On average, Americans want to live to be 91 years old, according to a recent Pew Research survey — a goal that has driven a

DUBLIN–(BUSINESS WIRE)–The “GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, Tirzepatide), Type (Patented, Biosimilars), Format (Single Dose, Multi-dose, Tablets), ROA (SC, Oral), Indication

We are very fortunate at AP to be able to view thousands of fantastic images each year. It’s not easy to choose a favourite but

JCM, Vol. 15, Pages 181: GLP-1 Receptor Agonists and SGLT2 Inhibitors in Stable Kidney Transplantation: Clinical Outcomes from a Cohort of Patients with Post-Transplant Diabetes

Amid global uncertainty, market expert Narendra Solanki advises theme-based investing. He highlights opportunities in specific metals like steel and copper, niche pharma plays focusing on

I valued Hims 6 months ago at ~$34/share. Back then my main thesis was that telehealth was a low-margin business, subscriber growth was fueled by

India’s obesity drug market is booming, poised for significant growth driven by rising lifestyle diseases and upcoming affordable generics. Experts anticipate wider access to GLP-1

The ex-girlfriend of Richie Sambora of Bon Jovi fame has also been hard at work on her eponymous fashion line which is available at Nordstrom.

As GLP-1 weight-loss drugs become more common, their effects may be reshaping everyday food choices in ways that extend far beyond individual health. When people

Key Points Eli Lilly is the clear leader in the burgeoning weight loss market. Its lineup and pipeline put it well ahead of even its

$NVO Quality GIGA-LONNNNNNNGGGGG!!! Novo Nordisk A/S Sponsored ADR Class B BATS:NVO MrJosephTrades This is a weekly of NVO, a global leader in pharmaceuticals addressing issues

How weight-loss drugs are reshaping fitness gyms  Axios 87% of Doctors Say Obesity Drugs Help Patients  동아비즈니스리뷰 | DBR Korea weighs reimbursing GLP‑1 obesity drugs amid rising